Skip to main content

We’ve updated our Terms & Conditions and Privacy Policy. By using this site, you agree to these terms.

Geisinger becomes the first member of Risant Health

DANVILLE, PA -- The National Institutes of Health is launching a Precision Medicine Initiative to engage 1 million Americans in health research. In order to ensure that Pennsylvania is part of this innovative approach to disease prevention and treatment, Geisinger is seeking input from participants in its MyCode Community Health Initiative.

Those already signed up for MyCode are asked to participate in an online survey, attend an open forum, or both. The information provided will help shape Geisinger's application to become a Precision Medicine site.

Lauded as a bold new research effort to revolutionize how we improve health and treat disease and launched with a $215 million investment in the President's 2016 Budget, the Precision Medicine Initiative aims to pioneer a new model of patient-powered research in order to accelerate biomedical discoveries and provide clinicians with new tools, knowledge, and therapies to select which treatments will work best for which patients.

In order to be part of this national initiative, current MyCode participants are asked to take a short survey before Jan. 24 at

In addition, MyCode participants can also attend one of three open forums to be held on Geisinger's Danville Campus in the Hood Auditorium: Thursday, Jan. 14 from 5 to 7 p.m.; Saturday, Jan. 16, from 1 to 3 p.m.; or Saturday, Jan. 23, from 9 to 11 a.m. No RSVP is necessary.

Geisinger patients who have not signed up but would like more information on how to be part of the MyCode Community Health Initiative can call 1-855-636-0019 or email

Already ahead of the national curve, Geisinger and research partner Regeneron Pharmaceuticals set out in January of 2014 to sequence 100,000 human exomes - the portion of the genome that contains disease-related information - through the MyCode Community Health Initiative. Less than two years later, more than 91,500 patients have already signed on and the goal has been broadened to 250,000 participants - a target that will make Geisinger a global leader in genetic research.
Content from General Links with modal content